HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Appropriators Hear Industry’s Self-Care Message, Ring Alarm About Menstrual Products

Executive Summary

OTC manufacturers would add endorsements to committee’s discussion of making more consumer health products available in US. In their report, appropriators both introduced a concern and added details to an existing statement about menstrual products.

You may also be interested in...



US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

PCPC, CHPA Ask US FDA To Defer Final Rulemaking On Sunscreen Actives In GRASE Limbo

Industry continues working to support updated GRASE findings for UV filters avobenzone, homosalate, octinoxate, octisalate, octocrylene, oxybenzone, ensulizole and meradimate, which the FDA categorized more than two years ago as lacking data, a position it reprised in 2021 under its overhauled OTC monograph system.

Facilitating More OTC Switches In US Graduates To Regulatory Plan On FDA’s Unified Agenda

For first time rules for novel switches and OTC hearings aids are parts of “significant regulatory actions” in agency’s plans. Information is added in Unified Agenda items explaining likely benefits and costs from the changes.

Topics

Latest News
UsernamePublicRestriction

Register

RS152654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel